Information Provided By:
Fly News Breaks for March 3, 2020
FATE
Mar 3, 2020 | 08:59 EDT
Guggenheim analyst Michael Schmidt raised the firm's price target on Fate Therapeutics to $41 from $25 and keeps a Buy rating on the shares after the company confirmed that 2020 is "set to be a data rich year." Expansion data on FT500, initial dose escalation data on FT516, and initial dose escalation data on FT596 are all set for read outs in the second half of the year while management also confirmed plans to submit two additional INDs in Q2, which will give Fate five wholly-owned iPSC-derived assets in the clinic, Schmidt noted.